Skip to content
Medical Health Aged Care

RACGP appoints new CEO

Royal Australian College of GPs 2 mins read

Georgina van de Water has been appointed as the new Chief Executive Officer of the Royal Australian College of GPs (RACGP).  

Ms van de Water will officially commence in the role as CEO on 5 April 2024, and Adjunct Associate Professor David Hillis will continue to act in an interim capacity until 4 April to allow for a transition period.

Before joining the RACGP as Chief General Practice Training Officer, Ms van de Water served as CEO for GP Synergy, the provider of the Australian General Practice Training (AGPT) program for specialist general practitioners in New South Wales and the Australian Capital Territory.

Prior to this, she was Chief Operating Officer at regional training provider and primary health network WentWest. She has also held senior roles both nationally and internationally in the private and not-for-profit sector.

RACGP Board Chair Dr Lara Roeske said Ms van de Water was unanimously selected by the Board as the RACGP’s next CEO after a robust executive search and selection process.

“Georgina is a talented and experienced leader with exceptional knowledge of the sector,” she said.

“Her experience in leading our GP training program will be invaluable. Georgina was essential to the success of our GP training program over the last year. In that time, the College effectively tripled its employees and added a diverse range of systems and sites across Australia while receiving positive feedback from our registrars.

“Georgina is adept in overseeing a wide variety of strategic and operational responsibilities, ensuring outstanding customer service by supporting employee development and performance. She also brings exceptional leadership and interpersonal skills and places a high value on ensuring engagement with and accountability to our members, registrars, and other stakeholders.

“Congratulations to Georgina on this next stage in her career!”

~ENDS

RACGP spokespeople are available for interviews: 03 8699 0992 / media@racgp.org.au.


About us:

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians.

Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here.


Contact details:

John Ronan
Media Adviser

Ally Francis
Media Adviser

Stuart Winthrope
Media Officer

Contact: 03 8699 0992media@racgp.org.au

Follow us on Twitter: @RACGP and Facebook.

Media

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.